Phase I/II dose escalation, pharmacokinetic, safety, and efficacy study of oral TAC-101 [amsilarotene] in patients with advanced hepatocellular carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 27 Jul 2012
At a glance
- Drugs Amsilarotene (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2012 Additional lead trial centre and drug company added as reported by ClinicalTrials.gov.
- 24 May 2010 Actual patient number (37) added as reported by ClinicalTrials.gov.